Publications

Filter Publications By:

GDC-0575 / Cancer

07/01/2011

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics

Single-Agent Inhibition of Chk1 Is Antiproliferative in Human Cancer Cell Lines In Vitro and Inhibits Tumor Xenograft Growth In Vivo

K. D. Davies, et al.

ARRY-502 / Asthma

06/26/2011

World Congress on Inflammation

Potent, Selective, and Orally Active CRTh2 Antagonists for Allergic Disease

L. Burgess, et al.

Ipatasertib / Cancer

06/07/2011

Cambridge Healthtech Institute Next Generation Kinase Inhibitors

Discovery of GDC-0068: A Selective ATP-competitive Akt Inhibitor for the Treatment of Human Tumors

J. F. Blake, et al.

GDC-0575 / Cancer

04/05/2011

American Association for Cancer Research Annual Meeting

Chk1 inhibition and Wee1 inhibition combine synergistically to inhibit cellular proliferation

K. D. Davies, et al.

Filanesib / Multiple Myeloma

04/04/2011

American Association for Cancer Research Annual Meeting

Combination of the KSP Inhibitor ARRY-520 with Bortezomib Causes Sustained Tumor Regressions and Significantly Increased Time to Regrowth in Bortezomib Sensitive and Resistant Models of Multiple Myeloma

R. Woessner, et al.

ARRY-380 / Breast Cancer

04/03/2011

American Association for Cancer Research Annual Meeting

ARRY-380: A Selective, Oral HER2 Inhibitor for the Treatment of Solid Tumors

K. Koch Ph.D.

ASLAN001 / Cancer

04/02/2011

American Association for Cancer Research Annual Meeting

Selective Inhibitors of the ErbB-Family of Receptor Tyrosine Kinase

E. Wallace, Ph.D.

GDC-0575 / Cancer

03/11/2011

International Symposium on Targeted Anticancer Therapies

Preclinical characterization of ARRY-575: A potent, selective, and orally bio-available small molecule inhibitor of Chk1

M. J. Humphries, et al.

Ipatasertib / Cancer

03/11/2011

International Symposium on Targeted Anticancer Therapies

Targeting the PI3K-Akt-mTOR pathway with GDC-0068, a novel selective ATP competitive Akt inhibitor

J. Tabernero, et al.

Ipatasertib / Cancer

02/26/2011

Bioorganic & Medicinal Chemistry Letters

Discovery of spirocyclic sulfonamides as potent Akt inhibitors with exquisite selectivity against PKA

R. Xu, et al.